Table 1. Distribution of 24 narcolepsy cases according to exposure status and patients’ characteristics.

Patient’s characteristics Mean ± SD/median/range	All cases (n = 24)	Not vaccinated or vaccinated after disease onset (n = 16)	Vaccinated before disease onset (n = 8)	p value*
Age (years)	24.0±14.3	26.1±13.1	19.9±16.6	0.20
	18.1	28.2	13.7
	6–55	8–55	6–50
Age group
<20 years of age	13 (54%)	7 (44%)	6 (75%)	0.21
≥20 years of age	11 (46%)	9 (56%)	2 (25%)
Male proportion	12 (50%)	10 (62.5%)	2 (25%)	0.19
Cases with cataplexy	16 (67%)	10 (63%)	6 (75%)	0.67
Cases with hypnagogic hallucinations	14/23 (61%)	9 (56%)	5/7 (71%)	0.66
Cases with sleep paralysis	10 (42%)	7 (44%)	3 (38%)	1.00
Cases with all signs and symptoms	5 (21%)	3 (19%)	2 (25%)	1.00
Diagnostic certainty
Brighton level 1	4 (17%)	2 (12.5%)	2 (25%)	0.73
Brighton level 2	12 (50%)	8 (50%)	4 (50%)
Brighton level 3	8 (33%)	6 (38%)	2 (25%)
HLA DQB1*0602 positive	19/24 (79%)	12/16 (75%)	7/8 (88%)	0.63
Interval between onset first sleep	53.3±93.1	72.3±116.9	24.8±27.5	1.00
symptoms and onset of cataplexy (days)	21	0	23
	0–330	0–330	0–91
Interval between disease onset and first	149.1±187.8	190.9±218.9	65.5±35.7	0.42
medical visit (days)	70.5	77.5	52.5
	3–799	3–799	32–124
Interval between disease onset and	427.8±244.52	482.1±239.3	319.3±231.4	0.15
confirmatory laboratory investigations	414	422	246
(days)	79–903	170–903	79–756

*Fisher exact test for proportions and Wilcoxon rank test for medians.